DRNK .0004- HUGE FDA NEWS!!!!! NOHO Signs Lette
Post# of 103014
(Total Views: 386)
Posted On: 04/27/2017 1:32:55 PM
DRNK .0004- HUGE FDA NEWS!!!!!
NOHO Signs Letter of Intent for FDA Registered Drug Formulation
Marketwired MarketwiredApril 27, 2017Comment
PHOENIX, AZ--(Marketwired - Apr 27, 2017) - NOHO, Inc. ( OTC PINK : DRNK ), a Wyoming corporation (the "Company"
, announced the following:
The Company has signed a letter of intent with DMR Biologic, LLC, of Schonfield, Wisconsin, to acquire the rights to market and sell its homeopathic OTC drug registered with the FDA.
This new formulation is taken via a patented, gel-based delivery method contained in a small stick pack. The product is taken sublingually (under the tongue), offering fast and effective relief from Hangover pain and headache. In bypassing the digestive system, the product is absorbed much faster than liquid or pill-based formulas and has no contraindicated drug interactions. The product's effectiveness is confirmed by multiple Double-blind/Placebo controlled clinical trials. Developed as a drug to treat migraine headaches, under the proposed deal, NOHO would have exclusive rights to the product in the Hangover market and register the new brand with the FDA and obtain a National Drug Code number. The proposed terms also include distribution for a re-branded migraine product which NOHO would market and sell through its new distributor, BNG Enterprises.
David Mersky, NOHO's CEO, stated, "In keeping with our strategy of pursuing undervalued assets like our 2oz Shot and Gold can products when we came into NOHO, we have once again found a great opportunity to bring an FDA compliant product to the Hangover market. As an OTC drug, this new formulation will make NOHO the market leader in the Hangover space, as none of the competition has clinically tested data to be able to make specific drug claims." Negotiations also involve NOHO working to re-launch a new iteration of the original migraine drug, called Lipigesic. Mersky continued, "I believe this is a great product that wasn't properly packaged and didn't have the appropriate marketing to support it. The test results are terrific and the migraine market is huge at around 50 million people. We're really good at identifying these hidden gems that require a dust-off and some re-branding. All the time, hard work and cost of the trials and FDA registration is already done."
In addition to the current formulation, the parties are discussing a hemp infused product for NOHO to bring to market. "We have identified a path to infuse Hemp, as a legal food product, into the formula. A Hemp-infused Hangover drug will fly off the shelves through our targeted distribution in smoke shops and vape stores," said NOHO's CEO David Mersky.
For additional information on NOHO please visit www.nohodrink.com and our full product site at www.imbutek.com and at www.instagram.com/nohodrink, as well as at www.twitter.com/nohodrink
$DRNK
NOHO Signs Letter of Intent for FDA Registered Drug Formulation
Marketwired MarketwiredApril 27, 2017Comment
PHOENIX, AZ--(Marketwired - Apr 27, 2017) - NOHO, Inc. ( OTC PINK : DRNK ), a Wyoming corporation (the "Company"
, announced the following: The Company has signed a letter of intent with DMR Biologic, LLC, of Schonfield, Wisconsin, to acquire the rights to market and sell its homeopathic OTC drug registered with the FDA.
This new formulation is taken via a patented, gel-based delivery method contained in a small stick pack. The product is taken sublingually (under the tongue), offering fast and effective relief from Hangover pain and headache. In bypassing the digestive system, the product is absorbed much faster than liquid or pill-based formulas and has no contraindicated drug interactions. The product's effectiveness is confirmed by multiple Double-blind/Placebo controlled clinical trials. Developed as a drug to treat migraine headaches, under the proposed deal, NOHO would have exclusive rights to the product in the Hangover market and register the new brand with the FDA and obtain a National Drug Code number. The proposed terms also include distribution for a re-branded migraine product which NOHO would market and sell through its new distributor, BNG Enterprises.
David Mersky, NOHO's CEO, stated, "In keeping with our strategy of pursuing undervalued assets like our 2oz Shot and Gold can products when we came into NOHO, we have once again found a great opportunity to bring an FDA compliant product to the Hangover market. As an OTC drug, this new formulation will make NOHO the market leader in the Hangover space, as none of the competition has clinically tested data to be able to make specific drug claims." Negotiations also involve NOHO working to re-launch a new iteration of the original migraine drug, called Lipigesic. Mersky continued, "I believe this is a great product that wasn't properly packaged and didn't have the appropriate marketing to support it. The test results are terrific and the migraine market is huge at around 50 million people. We're really good at identifying these hidden gems that require a dust-off and some re-branding. All the time, hard work and cost of the trials and FDA registration is already done."
In addition to the current formulation, the parties are discussing a hemp infused product for NOHO to bring to market. "We have identified a path to infuse Hemp, as a legal food product, into the formula. A Hemp-infused Hangover drug will fly off the shelves through our targeted distribution in smoke shops and vape stores," said NOHO's CEO David Mersky.
For additional information on NOHO please visit www.nohodrink.com and our full product site at www.imbutek.com and at www.instagram.com/nohodrink, as well as at www.twitter.com/nohodrink
$DRNK
(0)
(0)Scroll down for more posts ▼